Fms -like tyrosine kinase 3 positive acute myeloid leukemia.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
2
11
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
ppublish
Résumé
Fms -like tyrosine kinase 3 (FLT3) mutations are common in newly diagnosed patients with acute myeloid leukemia (AML). They are associated with a high risk of relapse. The identification of FLT3 mutations has important implications for the management of AML. FLT3 inhibitors have shown improved outcomes in FLT3-positive AML when used as a single agent in the salvage setting. However, the combination of inhibitors and chemotherapy in the first-line setting is the real game changer in FLT3mutant AML. The introduction of these drugs has improved the prognosis of FLT3-mutant AML, but the development of resistance is common. There are still many unanswered questions about FLT3-mutant AML. This article will analyze recent advances for FLT3-mutant AML, focusing on front-line therapy and post-transplant maintenance. Novel drug combinations and strategies against FLT3 mutated AML are currently under investigation and will be the focus of future studies. The development of more selective and potent FLT3 inhibitors may further improve outcomes for patients with FLT3-positive AML. Monitoring minimal residual disease and overcoming resistance are key issues for the future.
Identifiants
pubmed: 37820093
doi: 10.1097/CCO.0000000000000993
pii: 00001622-202311000-00019
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-593Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet 2023; 401:2073–2086.
Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J 2021; 11:41doi: 10.1038/s41408-021-00425-3.
doi: 10.1038/s41408-021-00425-3
Isidori A, Ferrara F. The changing landscape for patients with relapsed/refractory acute myeloid leukaemia. Curr Opin Oncol 2021; 33:635–641.
Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol 2020; 10:612880.
Daver N, Schlenk RF, Russel NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 2019; 33:299–312.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129:424–447.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140:1345–1377.
Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 2021; 138:2753–2767.
Jahn N, Jahn E, Saadati M, et al. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia 2022; 36:2218–2227.
Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017; 377:454–464.
Pratz KW, Cherry M, Altman JK, et al. A Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: final results. In Proceedings of the 62nd ASH Annual Meeting and Exposition, Virtual, 2 December 2020.
ClinicalTrials.gov. A study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy (HOVON 156 AML). 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT04027309 [accessed 22 May 2023].
Erba H, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401:1571–1583.
Schlenk RF, Montesinos P, Romero-Aguilar A, et al. Impact of allogeneic hematopoietic cell transplantation in first complete remission in addition to FLT3 inhibition with quizartinib in acute myeloid leukemia with FLT3-internal tandem duplication: results from the quantum-first trial. Blood 2022; 140:2130–2132.
Kadia T, Garcia-Manero G, Yilmaz M, et al. Venetoclax added to cladribine, idarubicin, and cytarabine with or without a FLT3 inhibitor in newly diagnosed acute myeloid leukemia. EHA Library. Proceedings of the EHA 25 virtual meeting 2020; E602.
Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 2015; 90:276–281.
Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3 -ITD mutated acute myeloid leukemia. Am J Hematol 2018; 93:1136–1141.
Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood 2022; 140:1845–1857.
Pratz K, Jonas B, Pullarkat V, et al. Long-term follow-up of the phase 3 viale—a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Blood 2022; 140: (Suppl 1): 529–531.
Döhner H, Pratz KW, DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. Blood 2022; 140: (Suppl 1): 1441–1444.
Konopleva M, Thirman MJ, Pratz KW, et al. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia. Clin Cancer Res 2022; 28:2744–2752.
Chua CC, Anstee NS, Enjeti AK, et al. High deliverability of a midostaurin triplet regimen incorporating venetoclax and low dose cytarabine in non-adverse cytogenetic risk acute myeloid leukaemia: a sub-analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study. Blood 2022; 140: (Suppl S1): 3362–3364.
Maiti A, Di Nardo C, Daver N. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 2021; 11:25.
Short N, DiNardo CD, Daver N, et al. Updated results from a Phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. Blood 2022; 140: (Suppl S1): 2007–2009.
Maziarz AT, Fernandez H, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transpl 2020; 56:1180–1189.
Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3–internal tandem duplication mutation (SORMAIN). J Clin Oncol 2020; 38:2993–3002.
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200–1228.
Daver N, Perl AE, Maly J, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia. J Clin Oncol 2022; 40:4048–4059.
Levis MJ, Hamadani M, Logan B. BMT-CTN 1506 (MORPHO): a randomized trial of the flt3 inhibitor gilteritinib as posttransplant maintenance for FLT3-ITD AML. In: Proceedings of the 23rd EHA Annual Meeting, LB 2711.